Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025) - Scorecard - MDSpire
Advertisement
Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025)
Clinical Scorecard: Analyzing the Research Landscape and Thematic Progression of Colitis Induced by Immune Checkpoint Inhibitors: A Bibliometric Study (2006-2025)
At a Glance
Category
Detail
Condition
Colitis induced by immune checkpoint inhibitors
Key Mechanisms
Immune checkpoint inhibitors enhance antitumor T-cell activity but can overstimulate the immune system, leading to immune-related adverse events (irAEs) such as colitis.
Target Population
Patients receiving immune checkpoint inhibitor therapy for cancer.
Care Setting
Oncology and immunotherapy clinics.
Key Highlights
1,010 papers analyzed on ICI-induced colitis from 62 countries.
United States leads in publication volume and citations.
Future research should focus on combination therapies and biomarkers.
Guideline-Based Recommendations
Diagnosis
Monitor for symptoms of colitis in patients receiving ICIs.
Management
Develop comprehensive management strategies for ICI-induced colitis.
Monitoring & Follow-up
Regular assessment of gastrointestinal symptoms in patients on ICIs.
Risks
Untreated colitis can lead to severe, life-threatening complications.
Patient & Prescribing Data
Patients undergoing treatment with immune checkpoint inhibitors.
Effective management strategies for ICI-induced colitis remain inadequate.
Clinical Best Practices
Prioritize research on fecal microbiota transplantation and predictive biomarkers.
